Stay updated on Pembrolizumab Maintenance in sNSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Maintenance in sNSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Maintenance in sNSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Both screenshots depict the same ClinicalTrials.gov record for NCT02564380, with no changes to core information like title, sponsor, location, eligibility criteria, or outcomes; any differences are limited to layout/visual formatting. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T13:52:25.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    34 days ago
    Change Detected
    Summary
    Major update: page now includes a funding-related operating status notice and announces version 3.2.0, replacing v3.1.0.
    Difference
    3%
    Check dated 2025-10-06T04:24:56.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Update to version v3.1.0; removal of several MedlinePlus topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) and archival of v3.0.2.
    Difference
    0.5%
    Check dated 2025-09-28T23:59:51.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.
    Difference
    0.2%
    Check dated 2025-09-14T18:50:01.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.
    Difference
    0.2%
    Check dated 2025-09-07T13:17:32.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name, location, and various drug safety topics, while removing extensive information related to lung cancer and several related medical terms.
    Difference
    3%
    Check dated 2025-08-31T10:07:06.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Maintenance in sNSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Maintenance in sNSCLC Clinical Trial page.